ARVINAS INC

Arvinas insider buys signal renewed confidence in its PROTAC oncology platform—late‑phase trials show 32% response, safe profile, and FDA orphan status.

Arvinas CFO’s routine tax‑withholding sale shows disciplined insider trading, not market warning, hinting steady confidence amid leadership changes.

Arvinas CSO Angela Cacace sells 2,576 shares at $7.60—an RSU tax‑withholding move that shows continued confidence amid a $70 million licensing deal and strong oncology prospects.

Arvinas insider sales on May 11, 2026 were tax‑driven and not a sign of declining confidence, even as a new Rigel/Pfizer licensing deal could boost profitability.

Arvinas insider buying shows executive confidence, while tax‑related CMO sales don’t dampen optimism—Phase 1 Parkinson data boosts the stock’s upside potential.

Arvinas insider sales reveal routine tax‑settlement, not strategic divestiture—insiders hold strong confidence while the company advances its PROTAC pipeline.